Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab and Cetuximab in Recurrent/Metastatic HNSCC
NCT02277197Phase 1Completed
- Sponsor
- James J. Lee
- Start
- Aug 2015
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ficlatuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by James J. Lee. Primary endpoint: Recommended Phase II Dose at 1 year. Started Aug 2015; status: completed.
02
Drugs
ficlatuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02277197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277197.